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Abstract 
Objective: To identify factors associated with acceptance of non-invasive ventilation (NIV) 
and gastrostomy in an exploratory population-based study. 
Methods: 78 people with ALS at least 6 months post-diagnosis, and 50 caregivers, were 
recruited from the South East ALS Register. Baseline physical, cognitive and psychological 
measures were obtained.  Three-monthly follow-ups monitored whether patients had 
accepted or refused NIV or gastrostomy. Following an intervention decision, post-decision 
interviews repeated baseline measures and included further intervention-specific 
questionnaires. 
Results: Thirty-two people with ALS made at least one intervention decision and of these 10 
decided about both NIV and gastrostomy. While illness factors predicted those needing to 
make an intervention decision, cognitive and education status, and level of executive 
dysfunction were associated with decision-making and acceptance or refusal of 
interventions. Patients’ understanding of their illness, their early approach to considering 
interventions and carer-related factors were also associated with treatment decisions. 
Conclusions: Our findings highlight the complexity of decision-making and provide a 
platform for designing further studies. Cognitive and psychosocial factors may assume a 
greater role in palliative care decisions for people with ALS than has been explicitly 
recognised. Future work must clarify how to ensure patients are not inadvertently being 
denied suitable interventions. 
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INTRODUCTION  
 
At late stages of Amyotrophic Lateral Sclerosis (ALS), symptoms of sleep-disordered 
breathing and latterly dyspnoea are managed using non-invasive ventilation (NIV) and 
dysphagia by gastrostomy.1-3  NIV improves survival and quality of life4 without increasing 
caregiver burden,5 and gastrostomy may also prolong survival.1 Thus understanding the 
factors influencing uptake of these interventions is important. 
 
Prospective studies have estimated NIV and gastrostomy uptake at between 7-36%.6 7 
Preliminary data on gastrostomy use in Scotland indicate an uptake of 11%.8 Little has been 
reported about uptake in England and Wales. In the UK, NIV referral rates are variable9 10 
and this is likely to apply to other countries.  
 
Demographic, psychological and disease-related factors have been shown to affect 
decision-making about NIV and gastrostomy by people with ALS.8 11-14  Early positive views 
towards gastrostomy and NIV are predictive of uptake when needed.15 16  People who derive 
less pleasure from oral intake or are unable to feed themselves independently are more 
likely to accept gastrostomy.17 This evidence on intervention uptake has mostly been derived 
from non-UK retrospective studies, most of which are clinic-based and therefore prone to 
bias. We therefore conducted a UK population-based prospective study investigating factors 
influencing decision-making about gastrostomy and NIV in ALS patients and caregivers. 
From a medical perspective, we predicted that significant weight loss, dysphagia and 
reduction in pleasure in eating would lead to uptake of gastrostomy, and that severe 
respiratory symptoms and sleep disruption would lead to uptake of NIV, with greater illness 
severity being evident in decision-makers. To improve interpretation of the findings and 
generate hypotheses for future research, we also explored cognitive and behavioural factors 
influencing decision-making, and investigated the specific beliefs patients had about their 
illness. 
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MATERIALS AND METHODS  
 
Participants 
 
Participants with a diagnosis of possible, laboratory-supported probable, probable or definite 
ALS18 were recruited from the South East ALS Register (SEALS),19 a population register 
covering the South-east region of England. Patients were 6-60 months post-diagnosis and 
had not been referred for either NIV or gastrostomy. We considered that patients might 
require time to adjust to the diagnosis and gain information, so defined eligibility at 6 months 
post-diagnosis. Caregivers, where present, were invited to participate in the study. Ethics 
approval was granted by the Joint South London and Maudsley and the Institute of 
Psychiatry Research Ethics Committee (11/H0807/1). Written informed consent was 
obtained from all participants consistent with the Declaration of Helsinki.  
  
 
Procedure 
 
Participants were assessed at study baseline on physical, cognitive, psychological and 
health service use measures (Table 1). They were also interviewed about interventions they 
might be offered in the future. Responses regarding NIV and gastrostomy were coded and 
classified for analysis as being either ‘active’ (e.g., actively seeking information and keen to 
find out more, or had considered information but no decision made at that point) or ‘passive’ 
(e.g., no mention of the intervention or aware of it but reluctant to think about it). 
 
Table 1 near here 
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Participants were followed-up at three-monthly intervals to monitor actual decision-making 
about NIV and gastrostomy and measure health service use (data to be reported 
elsewhere).    
 
We defined a decision as identification of a clinical need for an intervention and a clear 
decision made by the patient to accept or refuse it. This was confirmed by direct contact with 
the patient/caregiver, the healthcare professionals (HCPs) involved, or from clinic letters. 
Patients were considered decision-makers if they made at least one intervention decision 
during the course of the study. Patients who made more than one decision (either about 
different interventions or changed their mind over a specific intervention) were categorised 
as accepters or refuses based on the first decision made.  
 
When an intervention decision was made, patients and their caregivers were invited to 
participate in a post-decision assessment. For those agreeing to an intervention, the 
assessment occurred after gastrostomy placement or NIV trial. For those refusing an 
intervention, follow-up sessions were arranged as soon as possible after decision 
confirmation.  
 
 
Measures 
 
Baseline measures completed by/about the person with ALS and, where available a 
caregiver, are listed in Table 1. 
 
Post-decision, in addition to repeating baseline patient and caregiver measures, where 
feasible, we administered the Beliefs about Medicine Questionnaire (BMQ),34 modified to 
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measure patients’ beliefs about NIV or gastrostomy (as applicable), including the necessity 
for the intervention and their concerns about it.  
 
Statistical analysis  
 
Only a small group of people made a decision regarding NIV and gastrostomy so the 
statistical analysis is largely descriptive. We quantified the association between various 
variables and decision outcomes and ranked the associations to provide an ordering of 
hypotheses for future study. Associations between continuous or categorical baseline or 
post-decision variables and binary decision outcomes were quantified by standardized odds 
ratios measuring the change in odds of the outcome per one standard deviation change in 
the continuous predictor, or when changing the group, of a binary predictor. Odds ratios 
were generated by fitting logistic regression models. To rank the importance of the various 
associations, p-values from a test of independence were used. (NB: These multiple p-values 
cannot be interpreted as formal significance tests.)   
 
 
RESULTS 
 
Participants 
 
We invited a total of 178 patients identified between August 2008 - December 2011from the 
SEALS register to participate (see Figure 1 for study flowchart). Of these, 81 consented to 
participate (three were later excluded from the analysis after discovering they had made an 
intervention decision between invitation and baseline); of the remainder, 26 were no longer 
eligible (most had made an intervention decision), six died, six could not be contacted, two 
were not followed-up following advice from HCPs, and 57 declined participation (see Figure 
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1).  Seventy-eight people with ALS (44% of those initially identified) were included in the final 
analysis.  
 
 Figure 1 near here 
 
Sample characteristics at baseline 
 
The sample’s baseline age was 62.5 years (SD 11.8). Most participants were men (49/78) 
and had sporadic (65/78) and non-bulbar onset (65/78) ALS. Most were in a relationship 
(62/78), had no dependents (61/78) and were not employed (65/78). At baseline 
assessment, participants were on average 7.8 months post-diagnosis. The group had a 
mean WTAR-predicted premorbid IQ of 103.2 (SD 11.0), 12.4 (SD 3.4) years of education, 
and a slightly elevated mean post-illness onset Apathy score (FrSBe). Otherwise, there was 
an absence of marked psychological, cognitive or behavioural dysfunction (Table 2). When 
asked about interventions that might be offered in the future, 63% (49/78) of participants 
provided a ‘passive’ (versus ‘active’) response about gastrostomy and 71% (55/78) about 
NIV. 
 
Table 2 near here 
 
 
Intervention decisions made (See also Figure 2)  
 
Participants were followed up for on average 17.2 (SD 11.8) months until death or study end. 
Forty-two participants died during the study, 18 of these without making a decision. Of those 
who died, only 2 of the 24 (8.3%) who made a decision had lived alone, compared with 6 of 
the 18 (33.3%) who made no decision.  
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In total, 32 people (41%) made at least one intervention decision. Of these, 10 decided 
about both interventions. Nineteen people accepted and two refused NIV. Fifteen accepted 
and six refused gastrostomy. Two people who refused a gastrostomy subsequently agreed 
to one within the study timeframe. The majority of first decisions for the nine participants with 
bulbar onset who made decisions concerned gastrostomy (8/9 (89%) bulbar-onset decision-
makers); for those decision-makers with non-bulbar onset (23), 52% of first decisions (i.e. 
12/23) concerned NIV. Mean time from diagnosis to first decision was 21.1 months (SD 15.0 
months). In patients who died during the course of the study, NIV decisions were taken 
closer to end-of-life (mean 2.7 months (SD 2.2) prior to death) than gastrostomy decisions 
(mean 6.1 months (SD 4.2)) as found elsewhere3.  
 
 Figure 2 near here 
 
Decision-makers 
 
Associations between baseline variables and making a decision during the course of the 
study were quantified by means of odds ratios. Table 3 shows the 10 most important 
baseline variables (ranked according to p-value) in predicting whether a decision was made. 
We had predicted that significant weight loss, dysphagia and reduction in pleasure in eating 
would lead to uptake of gastrostomy, and that severe respiratory symptoms and sleep 
disruption would lead to uptake of NIV. Given our limited post NIV decision refusal data, we 
considered the two interventions together but in the overall decision-making process we 
found that being more unwell at study baseline (poorer speech and swallow, lower BMI, 
lower ALSFRS-R) and having poorer prognostic indicators (bulbar onset) were more likely to 
be associated with making a decision within the study’s timeframe. Importantly, some non-
illness variables were also associated with decision-making. Having a higher predicted 
premorbid IQ, more years of education and a more ‘active’ approach to gastrostomy and NIV 
at baseline (i.e. actively seeking information and keen to find out more, or had considered 
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information but had made no decision at baseline compared to those with a more passive 
approach who made no mention of the intervention or who were reluctant to think about it) 
were more likely to be associated with making a decision during the study. 
 
Table 3 near here 
 
 Factors best differentiating between intervention accepters and refusers 
 
Of the 32 participants who made ≥1 intervention decision, 21 agreed to complete a post-
decision session (Figure 2). Of the remaining 11, six died before a session could occur, 
three were too unwell, and two could not be contacted. Sessions occurred a median of 10.0 
months (range 3.3-34.0) following study baseline and 2.2 months (range 0.5-9.0) after the 
decision had been made. 
 
Variables that best differentiated between participants who accepted or refused an 
intervention were identified by calculating odds ratios to evaluate the association between 
baseline or post-decision variables and ‘refusal status’. The 10 variables most strongly 
associated with refusal were ranked according to p-values (Table 4). The most highly 
associated baseline variable was employment status: being employed at study entry was 
associated with subsequent refusal of an intervention. Those who felt they understood their 
illness less well, who appeared to have a more ‘active’ approach to interventions and those 
with fewer depressive symptoms at baseline were more likely subsequently to refuse an 
intervention. 
 
Table 4 near here 
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Family-rated executive function/behaviour at baseline and closer to the decision (rated at 
post-decision) may be a relevant predictor of intervention refusal. Those with greater FrSBe 
informant-rated Executive Dysfunction and Disinhibition pre-illness were more likely to 
refuse. Additionally, at baseline and post-decision, being less religious was more likely to 
predict intervention refusal. 
 
Post-decision those deriving more pleasure in eating were more likely to have refused an 
intervention. Pleasure in eating may be related to swallowing ability, which was also ranked 
highly. In addition, those who reported more concerns about gastrostomy and who felt it was 
less necessary were more likely to have refused. 
 
 
Caregivers 
 
A total of 50/65 available caregivers (17 men, 33 women), with mean age 57.6 (sd 12.2) 
years and a mean of 13.7 (sd 3.3) years of education completed measures at baseline; 
14/17 repeated measures at post-decision (Table 5). Most caregivers were spouses or 
partners (45/50) of study patients, but also included a granddaughter, friend and son. Twenty 
caregivers were working. Odds ratios indicated that reporting better general psychological 
well-being and lower caregiver strain at baseline and post-decision were more likely to be 
associated with caring for intervention-refusing patients. At baseline, the most important 
variable was palliative care outcome, with a better palliative care outcome score being 
associated with a greater likelihood of intervention refusal by the person with ALS. By post-
decision, however, refusers were more likely to be patients with a worse caregiver-rated 
palliative care outcome, perhaps resulting from refusing the intervention.  
 
Table 5 near here
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DISCUSSION 
 
This is the first prospective UK population-based study of the complex factors that influence 
how people with ALS make decisions about NIV and gastrostomy. Twenty-seven percent of 
our sample made a decision about each intervention during the study. In terms of 
intervention uptake, 19% accepted gastrostomy, broadly consistent with previous reports 
(e.g.6 7 16). NIV use, at 24%, was slightly higher than previously reported,9 possibly reflecting 
an increase in UK NIV referrals10 or recently published NIV guidelines for use in ALS.2 
 
This was an exploratory study to provide insights into the predictable complexity of these 
processes and thus lay the basis for future analyses with more participants and greater 
power to dissect factors implicated in this study. We found support for the expected 
importance of some illness-related physical factors in predicting the need for or uptake of 
interventions. However, the demonstration of the likely relevance of a range of psychological 
factors argues against the uncritical application of simplistic solutions (e.g., uncritical care 
pathway algorithms) for HCPs involved in advising people with ALS on choices relating to 
NIV and gastrostomy. 
 
 
Predictors of decision-making 
 
Most factors predicting decision-making were illness variables, with those more unwell at 
baseline more likely to make a decision about an intervention during the study. However, 
those with a higher predicted IQ, more years of education and a more active attitude towards 
interventions were also more likely to be decision-makers. Such patients may be more 
assertive in their consultations with HCPs or more active in their information-seeking about 
services and available interventions. Of concern, and important for future studies, those with 
lower IQ, fewer years of education and a more passive approach to interventions may be 
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disadvantaged in having less opportunity to make informed decisions. Future research might 
usefully explore whether systematic approaches to decision-making via the use, for 
example, of decision aids (e.g. 35-37) might enable professionals working with people with 
ALS to be more systematic in their approach with patients for whom decisions may become 
necessary, in order to reduce the potential bias in which patients find themselves making 
intervention-related decisions. 
 
Accepting vs. refusing interventions 
 
Baseline vital capacity and subsequent dysphagia and loss of pleasure in eating were 
associated with uptake of gastrostomy, although weight loss (BMI) was not strongly 
associated with decision status (Table 4). Potentially linked to these illness variables is the 
finding that baseline employment status predicted refusal. These findings may all relate to 
the participants’ perception of the physical need for the intervention, are consistent with 
previous studies,38 and highlight the importance of considering timing when offering the 
intervention. We were unable to evaluate whether severe respiratory symptoms and sleep 
disruption would lead to uptake of NIV, due to the small number of NIV refusers providing 
data for analysis.  
 
Although FrSBe-rated Apathy was the only clinically elevated baseline psychological-
symptom score, our results suggested greater family-rated pre-illness onset Executive 
Dysfunction and Disinhibition, and post-onset Executive Dysfunction scores were more 
strongly associated with intervention refusal. Such individuals may be less able to weigh up 
information, leading to a more concrete view of the intervention. Signs of executive 
dysfunction/disinhibition in the patient may also influence HCPs’ discussion of the 
intervention, possibly providing fewer details or emphasising difficulties with compliance. 
Elsewhere, an examination of epilepsy treatments396 found that clinicians’ presentation of 
options varied, subtly communicating their preferred option. Thus HCPs may communicate 
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their preferences to the patient, and may differ in the options presented depending on 
patient characteristics. The potential for inequitable provision of healthcare as an explanation 
for poorer prognosis in ALS patients with executive dysfunction has been raised 
elsewhere.25  
 
Other psychological characteristics were also associated with intervention acceptance or 
refusal. Patients with fewer depressive symptoms at baseline were more likely subsequently 
to refuse an intervention, suggesting that refusing an intervention was not simply related to 
the presence of earlier depressive symptoms being associated with a longer term wish not to 
prolong life by accepting an intervention. Indeed, refusers were those with a more active 
attitude to interventions, suggesting a more complex decision-making process than one that 
was simply mood related. Prior to needing either intervention, refusers were more likely to 
express a desire to seek out information, to be actively thinking about the intervention, or to 
have already decided what they would do if they needed the intervention in future. Refusers 
may, therefore, have had a more active approach to their disease management, perhaps 
reducing their tendency to comply unquestioningly with HCPs’ recommendations. Our finding 
that participants claiming to have no religious belief and to never attend religious services 
were more likely to refuse an intervention was consistent with previous findings whereby 
those opting to use NIV were more religious.14  
 
In addition, those who felt they understood their illness less well were more likely to refuse 
an intervention, suggesting it is important for people to feel they understand the illness (and 
related interventions) for them to accept an intervention. Those less concerned about and 
believing they had more control over their illness were also more likely to refuse. 
Furthermore, those who viewed gastrostomy as being less necessary and those with more 
concerns about gastrostomy were more likely to refuse interventions.  
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Caregiver variables 
 
Previous studies have not identified caregiver factors in decision-making.7 40 Our finding that 
caregivers with better general psychological well-being and lower strain at baseline and at 
the time of a decision were somewhat more likely to care for patients who refused an 
intervention, suggests that caregiver characteristics require consideration. We have 
previously also shown that the number of other caregiver dependents is predictive of 
caregivers’ psychological well-being41 and future research relating to intervention decisions 
might usefully investigate caregivers’ wider social context. The presence of caregivers may 
itself be important since, of those dying during the study, 91.67% of those making a decision 
had lived with a caregiver, compared with 66.6% who died without making a decision. Our 
findings in relation to the carer-rated PCOS focused on total PCOS scores; future research, 
however, could examine whether components of the PCOS (e.g. carer ratings of items 
relating to patients’ other symptoms, anxiety over the illness on the part of the patient or their 
family, reduced feelings of well-being` or the lack of dealing with practical affairs) contributed 
most to PCOS-related findings.    
 
 
 
Limitations 
 
Potential limitations of this study may affect the interpretation of our findings. Follow-up data 
were restricted because not all decision-makers participated in a post-decision interview. No 
follow-up data were available on those refusing NIV, since NIV decisions were taken closer 
to death than gastrostomy-related decisions, with those refusing likely to be more unwell. 
During recruitment, NICE guidelines for NIV were published; although we cannot determine 
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whether this influenced the rates of uptake of NIV by our sample, the majority of those dying 
without making a treatment decision did so prior to mid-2010, so the NIV guidelines may 
have changed the practice of offering NIV during the study. It is also possible those 
completing a post-decision session were not representative of all decision-makers.  
 
Analysis was based on grouping decisions about NIV and gastrostomy together. It is 
possible that decision-making about gastrostomy may be very different from decision-making 
about NIV. For example, gastrostomy could be perceived as a more physically-invasive 
procedure and less reversible than a decision to trial NIV would be.  
 
 
Conclusions 
 
This study provides a unique, prospective report on the actual decision-making of a 
population-based cohort of ALS patients and their caregivers in the UK. Our findings suggest 
that, rather than simply being limited to illness variables, IQ, education, employment status, 
religiosity, executive dysfunction and disinhibition, perceptions or beliefs about illness and 
interventions, and attitude to interventions or disease management from early in the disease 
may influence choices around NIV and gastrostomy. Our results therefore i) provide a 
potential broad framework to enhance understanding of the complexity of factors to be taken 
into account by HCPs advising people with ALS on choices relating to NIV and gastrostomy; 
ii) warn against simplistic algorithms to guide HCPs in assessing patient choices; and iii) 
argue for a ‘whole person’ biopsychosocial/spiritual understanding of patients’ decision-
making, especially at the level of the individual patient with ALS.  
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Table 1. Baseline measures completed by/about the person with ALS and their 
caregiver. 
People with ALS Baseline Measure 
 Illness 
variables 
ALS Functional Rating Scale- Revised (ALSFRS-R)20 
ALS Severity Scale, speech and swallowing subscales.21 
Single item, visual analogue scale to measure pleasure 
in eating (rating out of 10).17 
Vital capacity (% predicted). 
Height and weight (to calculate Body Mass Index - BMI). 
 Cognitive / 
behavioural 
measures  
Wechsler Test of Adult Reading (WTAR)22 to estimate 
premorbid IQ. 
Addenbrooke’s Cognitive Examination Revised (ACE-
R)23 to screen for early cognitive change. 
Frontal Systems Behavior Scale (FrSBe, Family-rated),24 
used in other studies of ALS (see 25) to assess everyday 
behavioural changes in the person with ALS in terms of 
apathy, executive dysfunction and disinhibition. 
 Psychological 
Measures 
Purpose in Life Scale (PILS)26 to assess patients’ views 
concerning the purpose they saw in their lives, attitudes 
to death and their freedom to make choices.  
Beck Depression Inventory-FastScreen (BDI)27: to 
screen for major depressive disorders and designed to 
measure psychological/non-somatic symptoms only. 
Brief Illness Perceptions Questionnaire (B-IPQ),28 a brief 
measure of illness perceptions in those who are very ill 
or elderly.  
Idler religiosity questionnaire29: a measure of public and 
private religiousness. 
Palliative Care Outcome Scale (POS)30: a 10-item scale 
which addressed issues relevant to palliative care. 
Carer Health status General Physical Health Rating (GPHR)31: a self-rating 
from 0 to 4 of the caregiver’s own physical health. 
 Psychological 
status 
Caregiver Strain Index (CSI)32: to measure strain 
experienced by informal caregivers.  
General Health Questionnaire (GHQ)33: to assess 
caregivers’ general psychological well-being 
 Proxy rating 
of palliative 
care  
Caregiver version of Palliative Care Outcome Scale 
(PCOS)30: to rate the problems for the patient and 
caregiver from the caregiver’s perspective.  
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Table 2: Characteristics of patients at baseline and post-decision  
 
 
 
Baseline  
measures for 
whole sample (max 
N =78) 
Baseline measures 
for subsequent 
decision-makers 
(max N=21) 
Measures 
obtained post-
decision (max 
N=21) 
 N  Descriptive N Descriptive N  Descriptive 
ALSFRS-R total (/48) #  
Mean (SD) 
78 35.1 (7.5) 21 34.4 (7.7) 21 22.1 (8.0) 
ALS Severity Scale – 
Speech (1-10) # Median 
(min-max) 
78 8.80 (2-10) 21 7.0 (2-10) 21 6.0 (1-10) 
ALS Severity Scale – 
Swallow (1-10) # Median 
(min-max) 
78 10.0 (6-10) 21 8.0 (6-10) 21 5.0 (2-10) 
Body Mass Index (BMI) 
Median (min-max) 
76 24.4 (15-
40) 
21 23.5 (15-33) 20 21.7 (12-
40) 
Vital capacity (% 
predicted) Mean (SD) 
68 73.8 (22.6) 18 74.1 (19.9) 12 52.8 (16.0) 
Pleasure in eating (/10) # 
Median (min-max) 
78 9.0 (0.5-10)  21 7.5 (0.5-10) 17/
17 
6.0 (0-10) 
ACE-R total (/100) # 
Mean (SD) 
53 90.7 (9.2) 14 91.9 (9.2) 3 86.7 (6.8) 
ACE-R verbal fluency 
(/14) # Mean (SD) 
71 10.9 (2.6) 20 11.6 (2.5) 6 10.5 (3.7) 
ACE-R language (/26) # 
Mean (SD) 
60 24.5 (2.2) 17 25.3 (1.2) 3 25.7 (0.6) 
ACE-R memory (/26) # 
Mean (SD) 
74 23.1 (3.5) 20 23.6 (3.6) 8 21.4 (2.9) 
ACE-R visual-spatial 
(/16) # Mean (SD) 
59 14.9 (1.8) 15 14.7 (2.4) 5 15.4 (0.6) 
ACE-R attention-
orientation (/18) # Mean 
(SD) 
76 17.4 (1.4) 20 17.6 (0.7) 8 17.4 (0.9) 
FrSBe Apathy pre-
illness* Median (min-
max) 
48 48.0 (32-
87) 
17 49.0 (37-67) 13 53.0 (35-
73)  
FrSBe Disinhibition pre-
illness * Median (min-
48 48.5 (34-
103) 
17 45.0 (37-66) 13 45.0 (39-
76) 
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max) 
FrSBe Executive 
dysfunction pre-illness* 
Mean (SD) 
47 50.1 (10.1) 16 48.6 (6.9) 13 49.5 (10.5) 
FrSBe Apathy post-
illness* Mean (SD) 
48 65.7 (16.6) 17 65.8 (18.3) 13 78.5 (14.5) 
FrSBe Disinhibition post-
illness* Median (min-
max) 
48 54.0 (34-
99) 
17 51.0 (38-66) 13 53.0 (39-
86) 
FrSBe Executive 
dysfunction  post-illness* 
Mean (SD) 
47 53.7 (11.4) 16 53.1 (8.8) 13 53.4 (8.9) 
Purpose in Life Scale 
(20-140) # Mean (SD) 
74 101.1 
(16.8) 
21 107.8 (15.9) 21 94.9 (17.9) 
Beck Depression 
Inventory (/21)* Median 
(min-max) 
74 3.0 (0-15) 21 2.0 (0-14) 21 3.5 (0-13) 
Palliative Care Outcome 
Scale (/40)* Mean (SD) 
74 10.5 (6.5) 21 10.1 (6.4) 20 11.5 (5.5) 
BIPQ: Effect on life 
(/10)* Mean (SD) 
73 7.0 (2.8) 20 6.7 (3.2) 21 8.1 (2.8) 
BIPQ: Timeline (/10)* 
Mean (SD) 
73 9.3 (1.7) 20 8.8 (2.2) 21 8.9 (2.8) 
BIPQ: Control over 
illness (/10)* Median 
(min-max) 
73 8.0 (0-10) 20 7.5 (0-10) 20 9.5 (4-10) 
BIPQ: Help from 
treatment (/10)* Mean 
(SD) 
72 6.7 (2.9) 20 6.4 (2.8) 20 6.9 (2.7) 
BIPQ: Symptoms (/10)*  
Mean (SD) 
72 6.4 (2.5) 20 6.2 (2.4) 20 7.6 (2.5) 
BIPQ: Concern about 
illness(/10)* Mean (SD) 
73 7.1 (3.1) 20 6.5 (3.4) 20 7.5 (3.3) 
BIPQ: Understand 
illness (/10)* Median 
(min-max) 
74 2.0 (0-8) 21 2.0 (0-8) 21 1.0 (0-10) 
BIPQ: Emotion effects 
(/10)* Mean (SD) 
74 6.3 (2.8) 21 5.9 (2.7) 21 6.7 (2.7) 
Idler: Has a religion: 51/2  12/9  14/  
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Yes/No 5 7 
Idler: Attend religious 
service: ≥1x Yr/Never 
38/3
6 
 11/1
0 
 12/
9 
Idler: Strength/comfort: 
Yes/No 
44/3
2 
 11/1
0 
 10/
11 
 
BMQ-Gastrostomy: 
Necessity (5-25)* Mean 
(SD) 
N/A  N/A  18 17.3 (4.4) 
BMQ-Gastrostomy: 
Concerns (5-25)* Mean 
(SD) 
N/A  N/A  18 13.6 (4.1) 
BMQ-Gastrostomy: 
Differential (-20-20) 
Median (min-max) 
N/A  N/A  18 3.5 (-7-13) 
BMQ-NIV: Necessity (5-
25)* Mean (SD) 
N/A  N/A  6 16.7 (4.3) 
BMQ-NIV: Concerns (5-
25)* Mean (SD) 
N/A  N/A  6 14.0 (4.2) 
BMQ-NIV: Differential (-
20-20) Median (min-
max) 
N/A  N/A  6 4.0 (-6-8) 
BMQ-General: Harm (4-
20)* Mean (SD) 
N/A  N/A  21 8.6 (2.6) 
BMQ-General: Overuse 
(3-15)* Mean (SD) 
N/A  N/A  21 8.8 (2.9) 
 
ALSFRS-R=ALS Functional Rating Scale Revised; ACE-R= Addenbrooke’s Cognitive Examination-
Revised; FrSBe=Frontal Systems Behavior Scale Family-rated (T scores reported: 60-64=borderline 
impairment; 65+=clinically elevated); Purpose in Life Scale (<92 Lack of purpose; 92-112 Indefinite; 
>112 Definite purpose); BIPQ=Brief Illness Perceptions Questionnaire; BMQ-
Gastrostomy/NIV/General=Belief in Medicines Questionnaire regarding gastrostomy/NIV/medicines in 
general; *High scores indicate more problems/ greater dysfunction or stronger agreement with 
statement; #High scores indicate fewer problems/less dysfunction. 
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Table 3: Relationship between variables at baseline patient data with decision-making status – 
Odds ratios ranked according to p-value 
Predictor 
measure  
Made at least one 
decision n=32 
Made no decision 
N=46 
OR 95% 
CI 
P 
value 
Adjusted 
OR* 
N Mean 
(sd) 
Median 
(min-
max) 
N Mean 
(sd) 
Median 
(min-
max) 
ALS-SS 
Speech (1-
10) 
32 8.06 
(2.15) 
9.0  
(2-10) 
46 9.26 
(1.32) 
10.00 
(4-10) 
0.48 0.28-
0.82 
0.007  
ALS-SS 
Swallow (1-
10) 
32 8.42 
(1.48) 
8.25 
(6-10) 
46 9.24 
(1.12) 
10 
(6-10) 
0.53 0.32-
0.86 
0.010  
WTAR-FSIQ 28 107.29 
(9.61) 
109.0 
(81-
117) 
43 100.51 
(11.12) 
103.0 
(75-117) 
2.07 1.15- 
3.73 
0.015 2.42 
BL attitude to 
gastrostomy 
(Passive 
/active) 
15
/ 
17 
  34 
/  
12 
  0.31 0.12-
0.81 
0.017 0.43 
BL attitude to 
NIV 
(Passive / 
Active) 
18 
/ 
14 
  37 
/ 
9 
  0.31 0.11-
0.86 
0.024 0.34 
Years of 
education 
32 13.53 
(4.13) 
13.00 
(3-23) 
46 11.67 
(2.66) 
11.00 (6-
20) 
1.80 1.08-
2.98 
0.024  
Region of 
onset 
(bulbar/other) 
9/
23 
  4/4
2 
  0.24 0.07-
0.88 
0.031  
BMI 32 23.80 
(4.03) 
23.40 
(14.9-
33.0) 
44 25.74 
(4.70) 
24.60 
(17.4-
40.2) 
0.62 0.37-
1.04 
0.069  
ACE-R 
attention- 
orientation 
(/18) 
30 16.97 
(1.99) 
18.0 (9-
18) 
46 17.61 
(0.75) 
18.00 
(15-18) 
0.58 0.32-
1.07 
0.081  
ALSFRS-R  
total (/48) 
32 33.38 
(7.50) 
35.50 
(18-44) 
46 36.35 
(7.38) 
37.50 
(13-47) 
0.67 0.42-
1.07 
0.090  
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ALS-SS=ALS Severity Scale; WTAR-FSIQ=Full-Scale IQ predicted by Wechsler Test of Adult 
Reading; BL=baseline; BMI=Body Mass Index; ACE-R=Addenbrooke’s Cognitive Examination-
Revised; ALSFRS-R=ALS Functional Rating Scale. *Adjusted for illness variables (ALS-SS Swallow, 
ALSFRS-R, BMI) Adjusted odds ratios were calculated to evaluate the association between WTAR-IQ 
or baseline attitude to NIV and gastrostomy and making a decision, after controlling for the effects of 
illness variables (BMI, ALSSS Swallow, ALSFRS-R). Holding the effect of illness variables constant 
increased the predictive effect of WTAR-IQ, but decreased slightly the predictive effects of baseline 
attitude to gastrostomy and NIV. 
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Table 4: Relationship between variables at baseline and post-decision and refusal status – 
Odds ratios ranked according to p-value 
Baseline measures 
Predictor 
measure  
Accepted intervention 
n=24 
Refused intervention  
N=8 
OR 95% CI P 
value 
N Mean 
(sd) 
Median 
(Min-
max) 
N Mean 
(sd) 
Median 
(Min-
max) 
Employed y/n 2/ 
22 
  4/4   0.09 0.01-
0.67 
0.02 
BIPQ: 
Understand 
illness (/10) 
23 1.87 
(2.56) 
0 (0-8) 7 4.14 
(2.61) 
5.00  
(1-8) 
2.27 0.95-
5.41 
0.07 
Vital capacity (% 
predicted) 
20 75.19 
(19.56) 
80.17 
(38.8-
108.3) 
7 58.54 
(18.20) 
56.37 
(30.4-
82.0) 
0.36 0.12-
1.10 
0.07 
FrSBe: 
Executive  
Dysfunction pre-
illness  
16 48.44 
(8.64) 
48.50 
(37-70) 
5 57.40 
(13.45) 
53.00  
(45-79) 
2.39 0.79-
7.20 
0.12 
FrSBe: 
Disinhibition pre-
illness 
17 46.71 
(8.17) 
45.00 
(36-66) 
5 56.20 
(15.99) 
48.00  
(45-83) 
3.27 0.71-
14.97 
0.13 
FrSBe: 
Executive  
dysfunction post-
illness 
16 52.19 
(11.13) 
52.50 
(37-79) 
5 61.80 
(11.63) 
64.00  
(50-79) 
2.41 0.75-
7.48 
0.13 
Idler: Attend 
religious service   
(≥ 1x Yr / never) 
14 / 
9 
  2/5   3.89 0.62-
24.52 
0.15 
BL Attitude to 
treatment: 
Passive/ active* 
13 / 
11 
  2/6   0.28 0.05-
1.69 
0.17 
ACE-R memory 
(/26)  
22 21.73 
(5.33) 
24.00  
(9-26) 
7 25.00 
(1.41) 
25.00 
(22-26) 
2.73 0.62-
12.02 
0.19 
BDI  (/21) 24 4.17 
(3.86) 
4.00  
(0-14) 
7 2.00 
(2.58) 
1.00  
(0-7) 
0.44 0.13-
1.48 
0.19 
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Post decision Max N=21 
Predictor 
measure 
Accepted intervention Refused intervention OR  95% CI P 
value N Mean 
(sd) 
Median 
(Min-
max) 
N Mean 
(sd) 
Median 
(Min-
max) 
Idler: Define as 
having a religion 
y/n 
13 
/3 
  1 
/ 
4 
  17.33 1.39-
216.60 
0.03 
BMQ-specific 
(Gast): Necessity 
(5-25)  
13 19.08 
(2.56) 
20.00 
(14-23) 
5 12.80 
(5.22) 
13.00  
(7-21) 
0.13 0.02-
0.86 
0.03 
BMQ-specific 
(Gast):  
Concerns (/10)  
13 12.38 
(3.86) 
11.00  
(7-20) 
5 16.60 
(3.21) 
18.00 
(11-19) 
3.68 0.90-
15.01 
0.07 
Idler: Attend 
religious service 
(≥ 1x Yr / never) 
11/
5 
  1 
/ 
4 
  8.80 0.77-
100.26 
0.08 
FrSBe: 
Executive  
dysfunction pre-
illness 
10 46.20 
(7.22) 
46.00 
(36-60) 
3 60.33 
(13.87) 
64.00 
(45-72) 
5.02 0.81-
31.10 
0.08 
Pleasure in 
eating  (/10) 
12 4.58 
(3.43) 
5.00 
(0-10) 
5 8.00 
(1.87) 
9.00 
(6-10) 
3.14 0.84-
11.65 
0.09 
BIPQ: Control 
over illness (/10) 
15 8.87 
(1.46) 
10.00  
(6-10) 
5 7.40 
(2.79) 
8.00  
(4-10) 
0.26 0.04-
1.64 
0.15 
BIPQ:  Concern 
about illness 
(/10) 
15 8.07 
(2.84) 
10.00  
(1-10) 
5 5.60 
(4.03) 
7.00  
(0-10) 
0.48 0.18-
1.32 
0.16 
FrSBe: 
Disinhibition pre-
illness 
10 47.70 
(11.50) 
43.50 
(39-76) 
3 59.00 
(3.61) 
60.00 
(55-62) 
4.20 0.56-
31.25 
0.16 
ALS-SS Swallow 
(/10)  
16 4.69 
(2.58) 
3.00 
(2-10) 
5 6.60 
(2.30) 
7.00 
(4-10) 
1.50 0.85-
2.64 
0.16 
 
BIPQ=Brief Illness Perceptions Questionnaire; FrSBe=Frontal Systems Behavior Scale; ACE-R 
memory=Addenbrooke’s Cognitive Examination-Revised memory subscale; BDI=Beck Depression 
Inventory-FastScreen; BMQ-specific (Gastrostomy): Necessity=Belief in Medicines Questionnaire, 
necessity of gastrostomy; BMQ-specific (Gastrostomy): Concerns=Belief in Medicines Questionnaire, 
REVISION of Manuscript ID MALS-2013-0186 
 
 
 
31 
concerns about gastrostomy; BIPQ=Brief Illness Perceptions Questionnaire; ALS-SS=ALS Severity 
Scale; *Baseline attitude to intervention that first decision was about. 
 
REVISION of Manuscript ID MALS-2013-0186 
 
 
 
32 
Table 5: Caregiver data at baseline and post-decision, including odds ratios for 
refusal status of patients 
Baseline N=50 
 Accepted intervention Refused intervention 
OR 
95% CI P 
value Predictor 
measure* N 
Mean 
(sd) 
Median  
(min-
max) 
N 
Mean 
(sd) 
Median  
(min-
max) 
1. PCOS (/40) 17 13.29 
(6.84) 
14.00  
(2-25) 
5 8.50 
(6.76) 
6.00  
(3-18) 
0.5 
 
0.2- 
1.4 
0.2 
2. GHQ (/36) 13 14.20 
(4.90) 
13.00  
(8-23) 
3 12.67 
(7.10) 
14.00  
(5-19) 
0.7 0.2-2.9 0.6 
3. CSI (/13) 17 6.24 
(3.51) 
6.00  
(1-13) 
5 5.60 
(4.72) 
4.00  
(1-12) 
0.8 
 
0.3- 
2.3 
0.7 
4. GPHR (0-4) 17 1.06 
(0.75) 
1.00  
(0-2) 
5 1.00 
(1.00) 
1.00  
(0-2) 
0.9  0.3- 
2.3 
0.9 
Post decision  N=14 
Predictor 
measure* 
Accepted intervention Refused intervention 
OR  95% CI 
P 
value 
N Mean 
(sd) 
Median 
(min-
max) 
N Mean 
(sd) 
Median 
(min-
max) 
GPHR (0-4) 11 1.45 
(0.82) 
2.00  
(0-2) 
3 0.33 
(0.58) 
0.00  
(0-1) 
0.2 0.0- 
1.3 
0.1 
CSI (/13) 11 8.73 
(2.69) 
10.00  
(5-13) 
3 5.33 
(3.06) 
6.00  
(2-8) 
0.2  
 
0.0- 
1.7 
0.1 
GHQ (/36) 9 17.00 
(3.71) 
18.00 
(10-22) 
2 13.00 
(7.07) 
13.00  
(8-18) 
0.3 0.0 -
2.3 
0.3 
PCOS (/40) 11 15.62 
(5.72) 
16.00 
(4-24) 
3 17.19 
(4.24) 
15.56 
(14-22) 
1.5  0.3-7.9 0.6 
 
 PCOS: Palliative Care Outcome Scale; GHQ: General Health Questionnaire; CSI: Caregiver Strain 
Index; GPHR: General Physical Health Rating; *High scores indicate greater strain, poorer health or 
well-being, or more problems. 
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 Figure 1: Flowchart showing recruitment pathway 
Eligibility unknown (n=30)
Patients potentially eligible for study during 
recruitment phase (n=393)
Eligible at 6 months post-diagnosis (n=198)
Not eligible at 6 months post-diagnosis (n= 
165)
•Symptom onset >5years (n=56)
•Decision made (n=80)
•RIP prior to invite (n=23)
•No capacity to consent (n=6)
Invited (n=178)
•Unable to contact (n=6)
•Advised not to follow-up invite (n=2)
•RIP after invite (n=6)
Not invited (n=20)
•Advised by HCPs inappropriate to invite (n=6)
•Requested not to be contacted re research (n=3)
•Moved out of area prior to invite (n=8)
•Could not contact/no current address (n=3)
Eligible at invite (n=138)
Not eligible at invite (n=26)
•Decision made (n=18)
•Incorrect diagnosis (n=7) 
•No capacity to consent (n=1)
Consented to study 
(n=81)
Declined participation (n=57)
•No reason given (n=19)
•Not ready to discuss it (n=12)
•Too busy (n=11)
•Too unwell (n=10)
•Disagreed with diagnosis (n=3)
•Participating in other research (n=2)
Included in analysis (n=78)
Excluded from analysis (n=3)
•Decision made between invite 
and baseline(n=3)
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Figure 2: Flow diagram showing decisions made by participants during the study 
 
 
            First decision made (could have been              All decisions made 
                   about NIV or gastrostomy)                                         
